Plasma levels of matrix metalloproteinase-2, -3, -10, and tissue inhibitor of metalloproteinase-1 are associated with vascular complications in patients with type 1 diabetes: The EURODIAB Prospective Complications Study

Cardiovascular Diabetology

Volumn 14, Issue 1, 2015, Pages

  Peeters, Stijn A ^a,b   Engelen, Lian ^a   Buijs, Jacqueline ^b   Chaturvedi, Nish ^c   Fuller, John H ^c   Schalkwijk, Casper G ^a   Stehouwer, Coen D ^a   Karamanos, B ^d   Kofinis, A ^d   Petrou, K ^d   Giorgino, F ^e   Picca, G ^e   Angarano, A ^e   de Pergola G , ^e   Laviola, L ^e   Giorgino, R ^e   Ionescu Tirgoviste, C ^f   Coszma, A ^f   Guja, C ^f   Songini, M ^g   Casu, A ^g   Pedron, M ^g   Pintus, S ^g   Fossarello, M ^g   Ferriss, J B ^h   Grealy, G ^h   O'Keefe, D ^h   Toeller, M ⁱ   Arden, C ⁱ   Rottiers, R ^j   Tuyttens, C ^j   Priem, H ^j   Ebeling, P ^k   Kylliainen, M ^k   Koivisto, V A ^k   Idzior Walus, B ^l   Sieradzki, J ^l   Cyganek, K ^l   Solnica, B ^l   Lemkes, H H P J ^m   Lemkes Stuffken, J C ^m   Nunes Correa, J ⁿ   Rogado, M C ⁿ   Gardete Correia, L ⁿ   Cardoso, M C ⁿ   Silva, A ⁿ   Boavida, J ⁿ   Machado Sa Marques, M ⁿ   Michel, G ^o   Wirion, R ^o   Cardillo, S ^o   Pozza, G ^p   Mangili, R ^r   Asnaghi, V ^p   Standl, E ^q   Schaffler, B ^q   Brand, H ^q   Harms, A ^q   Ben Soussan, M ^r   Verier Mine, O ^r   Fallas, P ^r   Fallas, M C ^r   Holloway, J ^c   Asbury, L ^c   Betteridge, D J ^c   Cathelineau, G ^s   Bouallouche, A ^s   Villatte Cathelineau, B ^s   Santeusanio, F ^t   Rosi, G ^t   D'Alessandro, V ^t   Cagini, C ^t   Bottini, P ^t   Reboldi, G P ^t   Navalesi, R ^u   Penno, G ^u   Bandinelli, S ^u   Miccoli, R ^u   Nannipieri, M ^u   Ghirlanda, G ^v   Saponara, C ^v   Cotroneo, P ^v   Manto, A ^v   Minnella, A ^v   Ward, J D ^w   Tesfaye, S ^w   Eaton, S ^w   Mody, C ^w   Borra, M ^x   Cavallo Perin, P ^x   Giunti, S ^x   Grassi, G ^x   Pagano, G F ^x   Porta, M ^x   Sivieri, R ^x   Vitelli, F ^x   Veglio, M ^x   Papazoglou, N ^y   Manes, G ^y   Muggeo, M ^z   Iagulli, M ^z   Cacciatori, V ^z   Cattedra di Malattie del Metabolismo, V ^z   Irsigler, K ^aa   Abrahamian, H ^aa   Walford, S ^ab   Sinclair, J ^ab   Hughes, S ^ab   McLelland, V ^ab   Ward, J ^ab   Roglic, G ^ac   Metelko, Z ^ac   Pepeonik, Z R ^ac   more..

^a MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^b Zuyderland Medical Centre   (Netherlands)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

^d HIPPOKRATION HOSPITAL   (Greece)

^e UNIVERSITY OF BARI   (Italy)

^f Clinic of Diabetes Nutrition and Metabolic Diseases   (Romania)

^g San Michele Hospital   (Italy)

^h University College Cork   (Ireland)

ⁱ HEINRICH HEINE UNIVERSITY   (Germany)

^j GHENT UNIVERSITY HOSPITAL   (Belgium)

^k HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^l JAGIELLONIAN UNIVERSITY   (Poland)

^m LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

ⁿ Portuguese Diabetes Association   (Portugal)

^o CENTRE HOSPITALIER DE LUXEMBOURG   (Luxembourg)

^p SAN RAFFAELE HOSPITAL   (Italy)

^q Klinikum Schwabing   (Germany)

^r CENTRE HOSPITALIER DE VALENCIENNES   (France)

^s SAINT LOUIS HOSPITAL   (France)

^t Dipartimento di Medicina Interna   (Italy)

^u Dipartimento di Endocrinologia e Metabolismo Ortopedia e Traumatologia e Medicina   (Italy)

^v CATHOLIC UNIVERSITY   (Italy)

^w ROYAL HALLAMSHIRE HOSPITAL   (United Kingdom)

^x UNIVERSITY OF TURIN   (Italy)

^y PAPAGEORGIOU GENERAL HOSPITAL   (Greece)

^z Diabetes Unit ^*  (Italy)

^aa City of Vienna Hospital Lainz   (Austria)

^ab NEW CROSS HOSPITAL   (United Kingdom)

^ac University of Zagreb   (Croatia)

more..

Author keywords

Albuminuria; Cardiovascular disease; Matrix metalloproteinase; Retinopathy; Tissue inhibitor of metalloproteinase; Type 1 diabetes

Indexed keywords

C REACTIVE PROTEIN; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; GELATINASE A; HEMOGLOBIN A1C; INTERLEUKIN 6; STROMELYSIN; STROMELYSIN 2; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TUMOR NECROSIS FACTOR ALPHA; VASCULAR CELL ADHESION MOLECULE 1; BIOLOGICAL MARKER; MMP10 PROTEIN, HUMAN; MMP2 PROTEIN, HUMAN; MMP3 PROTEIN, HUMAN; TIMP1 PROTEIN, HUMAN;

ADULT; ALBUMINURIA; ANGINA PECTORIS; ARTICLE; CARDIOMETABOLIC RISK; CARDIOVASCULAR DISEASE; CEREBROVASCULAR ACCIDENT; CORONARY ARTERY BYPASS GRAFT; ENDOTHELIAL DYSFUNCTION; FEMALE; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HUMAN; INFLAMMATION; INSULIN DEPENDENT DIABETES MELLITUS; MAJOR CLINICAL STUDY; MALE; MICROANGIOPATHY; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; RETINOPATHY; BLOOD; COHORT ANALYSIS; CROSS-SECTIONAL STUDY; DIABETES COMPLICATIONS; DIABETES MELLITUS, TYPE 1; EUROPE; MIDDLE AGED; PROSPECTIVE STUDY; VASCULAR DISEASES;

ADULT; BIOMARKERS; COHORT STUDIES; CROSS-SECTIONAL STUDIES; DIABETES COMPLICATIONS; DIABETES MELLITUS, TYPE 1; EUROPE; FEMALE; HUMANS; MALE; MATRIX METALLOPROTEINASE 10; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 3; MIDDLE AGED; PROSPECTIVE STUDIES; TISSUE INHIBITOR OF METALLOPROTEINASE-1; VASCULAR DISEASES;

EID: 84925234995     PISSN: None     EISSN: 14752840     Source Type: Journal    
DOI: 10.1186/s12933-015-0195-2     Document Type: Article

References (42)

1. Laing SP, Swerdlow AJ, Slater SD, Burden AC, Morris A, Waugh NR, et al. Mortality from heart disease in a cohort of 23,000 patients with insulin-treated diabetes. Diabetologia. 2003;46:760-5.
2. Soedamah-Muthu SS, Fuller JH, Mulnier HE, Raleigh VS, Lawrenson RA, Colhoun HM. High risk of cardiovascular disease in patients with type 1 diabetes in the U.K.: a cohort study using the general practice research database. Diabetes Care. 2006;29:798-804.
3. Snell-Bergeon JK, Nadeau K. Cardiovascular disease risk in young people with type 1 diabetes. J Cardiovasc Transl Res. 2012;5:446-62.
4. Galis ZS, Khatri JJ. Matrix metalloproteinases in vascular remodeling and atherogenesis: the good, the bad, and the ugly. Circ Res. 2002;90:251-62.
5. Kadoglou NP, Daskalopoulou SS, Perrea D, Liapis CD. Matrix metalloproteinases and diabetic vascular complications. Angiology. 2005;56:173-89.
6. Visse R, Nagase H. Matrix metalloproteinases and tissue inhibitors of metalloproteinases: structure, function, and biochemistry. Circ Res. 2003;92:827-39.
7. Thrailkill KM, Bunn RC, Moreau CS, Cockrell GE, Simpson PM, Coleman HN, et al. Matrix metalloproteinase-2 dysregulation in type 1 diabetes. Diabetes Care. 2007;30:2321-6.
8. Toni M, Hermida J, Goni MJ, Fernandez P, Parks WC, Toledo E, et al. Matrix metalloproteinase-10 plays an active role in microvascular complications in type 1 diabetic patients. Diabetologia. 2013;56:2743-52.
9. Gharagozlian S, Svennevig K, Bangstad HJ, Winberg JO, Kolset SO. Matrix metalloproteinases in subjects with type 1 diabetes. BMC Clin Pathol. 2009;9:7.
10. Jacqueminet S, Ben Abdesselam O, Chapman MJ, Nicolay N, Foglietti MJ, Grimaldi A, et al. Elevated circulating levels of matrix metalloproteinase-9 in type 1 diabetic patients with and without retinopathy. Clin Chim Acta. 2006;367:103-7.
11. Thrailkill KM, Moreau CS, Cockrell GE, Jo CH, Bunn RC, Morales-Pozzo AE, et al. Disease and gender-specific dysregulation of NGAL and MMP-9 in type 1 diabetes mellitus. Endocrine. 2010;37:336-43.
12. Giebel SJ, Menicucci G, McGuire PG, Das A. Matrix metalloproteinases in early diabetic retinopathy and their role in alteration of the blood-retinal barrier. Lab Invest. 2005;85:597-607.
13. Soedamah-Muthu SS, Chaturvedi N, Schalkwijk CG, Stehouwer CD, Ebeling P, Fuller JH. Soluble vascular cell adhesion molecule-1 and soluble E-selectin are associated with micro- and macrovascular complications in Type 1 diabetic patients. J Diabetes Complication. 2006;20:188-95.
14. Costacou T, Lopes-Virella MF, Zgibor JC, Virella G, Otvos J, Walsh M, et al. Markers of endothelial dysfunction in the prediction of coronary artery disease in type 1 diabetesThe Pittsburgh epidemiology of diabetes complications study. J Diabetes Complications. 2005;19:183-93.
15. Devaraj S, Cheung AT, Jialal I, Griffen SC, Nguyen D, Glaser N, et al. Evidence of increased inflammation and microcirculatory abnormalities in patients with type 1 diabetes and their role in microvascular complications. Diabetes. 2007;56:2790-6.
16. Chaturvedi N, Sjoelie AK, Porta M, Aldington SJ, Fuller JH, Songini M, et al. Markers of insulin resistance are strong risk factors for retinopathy incidence in type 1 diabetes. Diabetes Care. 2001;24:284-9.
17. Chaturvedi N, Bandinelli S, Mangili R, Penno G, Rottiers RE, Fuller JH. Microalbuminuria in type 1 diabetes: rates, risk factors and glycemic threshold. Kidney Int. 2001;60:219-27.
18. Schram MT, Chaturvedi N, Schalkwijk C, Giorgino F, Ebeling P, Fuller JH, et al. Vascular risk factors and markers of endothelial function as determinants of inflammatory markers in type 1 diabetes: the EURODIAB prospective complications study. Diabetes Care. 2003;26:2165-73.
19. Koivisto VA, Stevens LK, Mattock M, Ebeling P, Muggeo M, Stephenson J, et al. Cardiovascular disease and its risk factors in IDDM in Europe. EURODIAB IDDM complications study group. Diabetes Care. 1996;19:689-97.
20. Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro 3rd AF, Feldman HI, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150:604-12.
21. Aldington SJ, Kohner EM, Meuer S, Klein R, Sjolie AK. Methodology for retinal photography and assessment of diabetic retinopathy: the EURODIAB IDDM complications study. Diabetologia. 1995;38:437-44.
22. Fossati P, Prencipe L. Serum triglycerides determined colorimetrically with an enzyme that produces hydrogen peroxide. Clin Chem. 1982;28:2077-80.
23. Sugiuchi H, Uji Y, Okabe H, Irie T, Uekama K, Kayahara N, et al. Direct measurement of high-density lipoprotein cholesterol in serum with polyethylene glycol-modified enzymes and sulfated alpha-cyclodextrin. Clin Chem. 1995;41:717-23.
24. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972;18:499-502.
25. Nin JW, Ferreira I, Schalkwijk CG, Prins MH, Chaturvedi N, Fuller JH, et al. Levels of soluble receptor for AGE are cross-sectionally associated with cardiovascular disease in type 1 diabetes, and this association is partially mediated by endothelial and renal dysfunction and by low-grade inflammation: the EURODIAB prospective complications study. Diabetologia. 2009;52:705-14.
26. Opstad TB, Pettersen AA, Weiss TW, Akra S, Ovstebo R, Arnesen H, et al. Genetic variation, gene-expression and circulating levels of matrix metalloproteinase-9 in patients with stable coronary artery disease. Clin Chim Acta. 2012;413:113-20.
27. Derosa G, Cicero AF, Scalise F, Avanzini MA, Tinelli C, Peros E, et al. Metalloproteinases in diabetics and nondiabetics during acute coronary syndromes and after 3 months. Endothelium. 2007;14:175-83.
28. Kelly D, Khan SQ, Thompson M, Cockerill G, Ng LL, Samani N, et al. Plasma tissue inhibitor of metalloproteinase-1 and matrix metalloproteinase-9: novel indicators of left ventricular remodelling and prognosis after acute myocardial infarction. Eur Heart J. 2008;29:2116-24.
29. Lu L, Zhang Q, Pu LJ, Peng WH, Yan XX, Wang LJ, et al. Dysregulation of matrix metalloproteinases and their tissue inhibitors is related to abnormality of left ventricular geometry and function in streptozotocin-induced diabetic minipigs. Int J Exp Pathol. 2008;89:125-37.
30. Suzuki D, Miyazaki M, Jinde K, Koji T, Yagame M, Endoh M, et al. In situ hybridization studies of matrix metalloproteinase-3, tissue inhibitor of metalloproteinase-1 and type IV collagen in diabetic nephropathy. Kidney Int. 1997;52:111-9.
31. Hosoyamada Y, Sakai T. Structural arrangement of collagen fibrils in the periarterial connective tissue of the kidney: their functional relevance as a structural stabilizer against arterial pressure. Anat Sci Int. 2012;87:80-7.
32. Alter ML, Kretschmer A, Von Websky K, Tsuprykov O, Reichetzeder C, Simon A, et al. Early urinary and plasma biomarkers for experimental diabetic nephropathy. Clin Lab. 2012;58:659-71.
33. Salzmann J, Limb GA, Khaw PT, Gregor ZJ, Webster L, Chignell AH, et al. Matrix metalloproteinases and their natural inhibitors in fibrovascular membranes of proliferative diabetic retinopathy. Br J Ophthalmol. 2000;84:1091-6.
34. Mohammad G, Kowluru RA. Matrix metalloproteinase-2 in the development of diabetic retinopathy and mitochondrial dysfunction. Lab Invest. 2010;90:1365-72.
35. Jung K, Gerlach RF, Tanus-Santos JE. Preanalytical pitfalls of blood sampling to measure true circulating matrix metalloproteinase 9 and tissue inhibitors of matrix metalloproteinases. Clin Chim Acta. 2006;373:180-1. author reply 182.
36. McQuibban GA, Gong JH, Tam EM, McCulloch CA, Clark-Lewis I, Overall CM. Inflammation dampened by gelatinase a cleavage of monocyte chemoattractant protein-3. Science. 2000;289:1202-6.
37. McQuibban GA, Gong JH, Wong JP, Wallace JL, Clark-Lewis I, Overall CM. Matrix metalloproteinase processing of monocyte chemoattractant proteins generates CC chemokine receptor antagonists with anti-inflammatory properties in vivo. Blood. 2002;100:1160-7.
38. Chase AJ, Newby AC. Regulation of matrix metalloproteinase (matrixin) genes in blood vessels: a multi-step recruitment model for pathological remodelling. J Vasc Res. 2003;40:329-43.
39. Montero I, Orbe J, Varo N, Beloqui O, Monreal JI, Rodriguez JA, et al. C-reactive protein induces matrix metalloproteinase-1 and -10 in human endothelial cells: implications for clinical and subclinical atherosclerosis. J Am Coll Cardiol. 2006;47:1369-78.
40. Akahane T, Akahane M, Shah A, Connor CM, Thorgeirsson UP. TIMP-1 inhibits microvascular endothelial cell migration by MMP-dependent and MMP-independent mechanisms. Exp Cell Res. 2004;301:158-67.
41. Raffetto JD, Khalil RA. Matrix metalloproteinases and their inhibitors in vascular remodeling and vascular disease. Biochem Pharmacol. 2008;75:346-59.
42. Brew K, Nagase H. The tissue inhibitors of metalloproteinases (TIMPs): an ancient family with structural and functional diversity. Biochim Biophys Acta. 1803;2010:55-71.